ReviewStem cell research & therapy2025
From mitochondria to immune networks: new mesenchymal stem cell strategies to treat periodontitis.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Immune Microenvironment Engineering for Functional Periodontal Regeneration: Mechanisms, Biomaterial Strategies, and Translational Perspectives.Biotechnology journal · 2026Review
- A mitochondria-targeted nanoantioxidant restores alveolar bone homeostasis in periodontitis by quenching ROS and suppressing the cGAS-STING pathway.Bioactive materials · 2026Article
- A new perspective on mesenchymal stem cells and their derivatives in alleviating cerebral ischemia-reperfusion injury dynamically regulating mitochondrial function to remodel the immune network.Cell death & disease · 2026Review
- Metabolomics-guided Mechanisms of Mesenchymal Stromal Cell and Exosome Therapies in Chronic Diseases.Stem cell reviews and reports · 2026Review
- Periodontitis-Induced Immune Reprogramming: Implications for Cancer Immunotherapy Response.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis is a chronic inflammatory disease that damages periodontal tissues and is mainly caused by immune dysfunction. Current treatments, such as mechanical debridement and adjunctive antimicrobial, work poorly; periodontal surgery brings pain and complications.Mesenchymal stem cells (MSCs) have a powerful ability to regulate immune responses and great potential for tissue regeneration, thus attracting extensive attention in the field of periodontal treatment. However, in the microenvironment of chronic periodontal inflammation, the therapeutic effect of MSCs is severely inhibited. Recent studies show that MSCs can transfer mitochondria to change energy metabolism, thereby regulating immune cell differentiation and function, lowering local immune responses. Therefore, this review proposes an innovative strategy of treating periodontitis using mitochondrial transfer by MSCs. It explores how mitochondrial transfer helps restore energy metabolism, reduce oxidative stress, and regulate immune cell function. This approach may reshape the immune-metabolic network in the periodontal microenvironment, reduce local chronic inflammation, and promote periodontal tissue regeneration.With the development of new technologies, treatments based on mitochondrial transfer from MSCs are expected to become more accurate and efficient in future clinical applications. In addition, this review introduces the "organ-immune-metabolism" three-dimensional regeneration model, which integrates organ repair, immune regulation, and metabolic reprogramming. We hope this review may offer new therapeutic insights for researchers in oral biology and periodontists treating periodontitis and other immune-related diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.